Holen Sie sich die Stockscreener-App
22.61
6.80%
1.44
Handel nachbörslich:
22.61
Schlusskurs vom Vortag:
$21.17
Offen:
$21.22
24-Stunden-Volumen:
226.54K
Relative Volume:
1.16
Marktkapitalisierung:
$959.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-161.15M
KGV:
-6.0863
EPS:
-3.7149
Netto-Cashflow:
$-138.61M
1W Leistung:
+20.84%
1M Leistung:
+22.15%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$21.22
$22.94
1-Wochen-Bereich:
$18.84
$22.94
52-Wochen-Spanne:
$12.24
$22.94
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
650-839-4360
Adresse
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
22.61 | 898.38M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight2026 Funding Rounds & List of Investors - Tracxn
Maplight Therapeutics (NASDAQ:MPLT) Reaches New 52-Week HighHere's Why - MarketBeat
MPLT Earnings History & Surprises | EPS & Revenue Results | MAPLIGHT THERAPEUTICS INC (NASDAQ:MPLT) - ChartMill
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
All News for MPLT : MapLight Therapeutics, Inc. - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Issues Quarterly Earnings Results, Misses Estimates By $1.42 EPS - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MapLight Therapeutics Announces 2025 Financial Results, Advances Clinical Pipeline for Schizophrenia, Autism, and Alzheimer’s Trials - Minichart
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 5.6%What's Next? - MarketBeat
MapLight Therapeutics 2023 Annual Report: Innovative CNS Drug Discovery, Pipeline, and Risk Factors Overview - Minichart
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position - TipRanks
Stifel reiterates Buy rating on MapLight Therapeutics stock By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on MapLight Therapeutics stock - Investing.com
MapLight Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MapLight Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
MapLight Therapeutics 10-K: Revenue $0, Net loss $161.2M - TradingView
[10-K] MapLight Therapeutics, Inc. Files Annual Report - Stock Titan
Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share - MarketScreener
MapLight Therapeutics (NASDAQ: MPLT) widens 2025 loss but funds runway through 2027 - Stock Titan
Two Phase 2 readouts ahead as MapLight says cash lasts through 2027 - Stock Titan
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - MarketScreener
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - tipranks.com
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Finviz
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
MapLight $251M IPO Defies Market Slowdown Amid Federal Shutdown - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
MapLight Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $186,301.84 in Stock - Defense World
MapLight Therapeutics Insiders Signal Confidence with Share Purchases () - aktiencheck.de
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maplight Therapeutics Inc-Aktie (MPLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malenka Robert C. | Director |
Feb 20 '26 |
Sale |
18.03 |
2,195 |
39,576 |
337,059 |
| Malenka Robert C. | Director |
Feb 24 '26 |
Sale |
18.15 |
736 |
13,358 |
325,059 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):